[go: up one dir, main page]

WO2003029485A3 - Specific differential display arrays - Google Patents

Specific differential display arrays Download PDF

Info

Publication number
WO2003029485A3
WO2003029485A3 PCT/DK2002/000653 DK0200653W WO03029485A3 WO 2003029485 A3 WO2003029485 A3 WO 2003029485A3 DK 0200653 W DK0200653 W DK 0200653W WO 03029485 A3 WO03029485 A3 WO 03029485A3
Authority
WO
WIPO (PCT)
Prior art keywords
differential display
specific differential
display arrays
stressed
identifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2002/000653
Other languages
French (fr)
Other versions
WO2003029485A2 (en
Inventor
Jens Bitsch-Noerhave
Kenneth Thirstrup
Rene Hummel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azign Bioscience AS
Original Assignee
Azign Bioscience AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azign Bioscience AS filed Critical Azign Bioscience AS
Priority to EP02800000A priority Critical patent/EP1434883A2/en
Publication of WO2003029485A2 publication Critical patent/WO2003029485A2/en
Publication of WO2003029485A3 publication Critical patent/WO2003029485A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a method for identifying a gene fragment that is differentially expressed in a non-stressed and stressed state of a biological source, said method comprising i) identifying a gene that is differentially expressed in a non-stressed and stressed state, and ii) identifying a fragment of the identified gene, said fragment comprising a non-conserved region.
PCT/DK2002/000653 2001-10-02 2002-10-02 Specific differential display arrays Ceased WO2003029485A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02800000A EP1434883A2 (en) 2001-10-02 2002-10-02 Specific differential display arrays

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101438 2001-10-02
DKPA200101438 2001-10-02

Publications (2)

Publication Number Publication Date
WO2003029485A2 WO2003029485A2 (en) 2003-04-10
WO2003029485A3 true WO2003029485A3 (en) 2004-03-04

Family

ID=8160744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000653 Ceased WO2003029485A2 (en) 2001-10-02 2002-10-02 Specific differential display arrays

Country Status (2)

Country Link
EP (1) EP1434883A2 (en)
WO (1) WO2003029485A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946177B2 (en) 2004-11-12 2015-02-03 Mima Therapeutics, Inc Methods and compositions involving miRNA and miRNA inhibitor molecules

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118806A2 (en) 2004-05-28 2005-12-15 Ambion, Inc. METHODS AND COMPOSITIONS INVOLVING MicroRNA
JP2010510964A (en) 2006-09-19 2010-04-08 アシュラジェン インコーポレイテッド MiR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292 as targets for therapeutic intervention Genes and pathways regulated by 3p
EP2115138A2 (en) 2006-09-19 2009-11-11 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
EP2542678B1 (en) 2010-03-04 2017-04-12 InteRNA Technologies B.V. A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
NZ605420A (en) 2010-07-06 2015-02-27 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
BR112013012265A2 (en) 2010-11-17 2016-08-02 Asuragen Inc mirnas as biomarkers to distinguish benign from malignant thyroid neoplasms
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
EP2681566A2 (en) 2011-02-28 2014-01-08 University of Iowa Research Foundation Anti-müllerian hormone changes in pregnancy and prediction ofadverse pregnancy outcomes and gender
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US20130157884A1 (en) 2011-10-26 2013-06-20 Asuragen, Inc. Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
WO2013063544A1 (en) 2011-10-27 2013-05-02 Asuragen, Inc. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors
EP2870263A1 (en) 2012-07-03 2015-05-13 InteRNA Technologies B.V. Diagnostic portfolio and its uses
WO2014055117A1 (en) 2012-10-04 2014-04-10 Asuragen, Inc. Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
CA2905949A1 (en) 2013-03-15 2014-09-25 Baylor Research Institute Ulcerative colitis (uc)-associated colorectal neoplasia markers
US9868992B2 (en) 2013-03-15 2018-01-16 Baylor Research Institute Tissue and blood-based miRNA biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer
ES2935257T3 (en) 2013-03-15 2023-03-03 Univ Chicago Methods and Compositions Related to T Cell Activity
JP2021501594A (en) 2017-11-03 2021-01-21 インテアールエヌエー テクノロジーズ ビー．ヴイ．ＩｎｔｅＲＮＡ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． MiRNA molecules, equivalents, antagomils, or sources thereof for treating and / or diagnosing conditions and / or diseases associated with neuronal defects, or for neuronal regeneration / development.
CN108663462B (en) * 2018-08-06 2021-04-13 通标标准技术服务(上海)有限公司 Method for measuring vitamin A, D and E in milk powder
US12441716B2 (en) 2019-04-12 2025-10-14 The Regents Of The University Of California Compositions and methods for increasing muscle mass and oxidative metabolism
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051789A2 (en) * 1997-05-13 1998-11-19 Display Systems Biotech A/S A METHOD TO CLONE mRNAs AND DISPLAY OF DIFFERENTIALLY EXPRESSED TRANSCRIPTS (DODET)
WO1999049894A1 (en) * 1998-04-01 1999-10-07 Genentech, Inc. Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders
WO1999055913A2 (en) * 1998-04-27 1999-11-04 Sidney Kimmel Cancer Center Reduced complexity nucleic acid targets and methods of using same
WO2000000646A1 (en) * 1998-06-30 2000-01-06 The Scripps Research Institute METHOD FOR SIMULTANEOUS IDENTIFICATION OF DIFFERENTIALLY EXPRESSED mRNAs AND MEASUREMENT OF RELATIVE CONCENTRATIONS
GB2350676A (en) * 1999-06-01 2000-12-06 Proteome Sciences Plc Method of screening for an agent for treating insulin-related disorders
WO2001002560A1 (en) * 1999-06-29 2001-01-11 Autogen Research Pty. Ltd. Novel genes and their use in the modulation of obesity, diabetes and energy imbalance
WO2001063295A2 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Ltd. Dpi-6, a therapeutic biomarker in neurological disorders
WO2002095064A1 (en) * 2001-05-18 2002-11-28 Azign Bioscience A/S Transporter arrays and methods and kits for producing and using the arrays

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051789A2 (en) * 1997-05-13 1998-11-19 Display Systems Biotech A/S A METHOD TO CLONE mRNAs AND DISPLAY OF DIFFERENTIALLY EXPRESSED TRANSCRIPTS (DODET)
WO1999049894A1 (en) * 1998-04-01 1999-10-07 Genentech, Inc. Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders
WO1999055913A2 (en) * 1998-04-27 1999-11-04 Sidney Kimmel Cancer Center Reduced complexity nucleic acid targets and methods of using same
WO2000000646A1 (en) * 1998-06-30 2000-01-06 The Scripps Research Institute METHOD FOR SIMULTANEOUS IDENTIFICATION OF DIFFERENTIALLY EXPRESSED mRNAs AND MEASUREMENT OF RELATIVE CONCENTRATIONS
GB2350676A (en) * 1999-06-01 2000-12-06 Proteome Sciences Plc Method of screening for an agent for treating insulin-related disorders
WO2001002560A1 (en) * 1999-06-29 2001-01-11 Autogen Research Pty. Ltd. Novel genes and their use in the modulation of obesity, diabetes and energy imbalance
WO2001063295A2 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Ltd. Dpi-6, a therapeutic biomarker in neurological disorders
WO2002095064A1 (en) * 2001-05-18 2002-11-28 Azign Bioscience A/S Transporter arrays and methods and kits for producing and using the arrays

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRED REGNIER ET AL: "Multidimensional Chromatography and the Signature Peptide Approach to Proteomics", LCGC, vol. 19, no. 2, February 2001 (2001-02-01), pages 200 - 213, XP002232798, Retrieved from the Internet <URL:http:www.chromatographyonline.com> [retrieved on 20030226] *
GYGI STEVEN P ET AL: "Quantitative analysis of complex protein mixtures using isotope-coded affinity tags.", NATURE BIOTECHNOLOGY, vol. 17, no. 10, October 1999 (1999-10-01), pages 994 - 999, XP002232658, ISSN: 1087-0156 *
YAMANO MAYUMI ET AL: "Corticotropin-releasing hormone1 receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 292, no. 1, January 2000 (2000-01-01), pages 181 - 187, XP002232660, ISSN: 0022-3565 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946177B2 (en) 2004-11-12 2015-02-03 Mima Therapeutics, Inc Methods and compositions involving miRNA and miRNA inhibitor molecules

Also Published As

Publication number Publication date
WO2003029485A2 (en) 2003-04-10
EP1434883A2 (en) 2004-07-07

Similar Documents

Publication Publication Date Title
WO2003029485A3 (en) Specific differential display arrays
AU2002336367A1 (en) Adamts13 genes and proteins and variants, and uses thereof
AU2002365811A1 (en) Methods for the selection and cloning of nucleic acid molecules free of unwanted nucleotide sequence alterations
AU2001238212A1 (en) Modified fluorescent proteins
WO2003012089A3 (en) Crystal structure of beta-site app cleaving enzyme (bace) and use thereof
AU2002368056A1 (en) Novel pla2 enzyme, it&#39;s antibody, enzyme inhibitor and use and the preparation methods thereof
AU2002243750A1 (en) Novel nucleic acid and polypeptide molecules
EP1369477A4 (en) METHOD OF CONSTRUCTING cDNA TAG FOR IDENTIFYING EXPRESSED GENE AND METHOD OF ANALYZING GENE EXPRESSION
WO2004029835A3 (en) System and method for associating different types of media content
WO2003010309A1 (en) Oligonucleotides for detecting tubercle bacillus and method therefor
AU2002254438A1 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
AU2002323612A1 (en) Novel clark protein and nucleic acid molecules and uses therefor
EP1383871A4 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2003050748A3 (en) Genetic analysis of gene expression in heterosis
AU2001238676A1 (en) System and method for providing transparent and anonymous transactions for the internet
AU2002303137A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
EP1383908A4 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2002101393A3 (en) Method for identifying interaction between proteins and dna fragments of a genome
WO2002063013A3 (en) Human acid phosphatase gene
AU2002257016A1 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
EP1383876A4 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
AU2002239227A1 (en) Isolated human enzyme, nucleic acid molecules encoding human enzyme, and uses thereof
AU2002330205A1 (en) Isolated cryopyrins, nucleic acid molecules encoding these, and use thereof
AU2002243460A1 (en) Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof
AU2002307004A1 (en) Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002800000

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002800000

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002800000

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP